Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia

May 21, 2026 updated by: Lixin Xie, Chinese PLA General Hospital

A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli

Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
      • Beijing, China
        • 1st Medical Center of Chinese PLA General Hospital
        • Contact:
      • Beijing, China
        • 8th Medical Center of Chinese PLA General Hospital
        • Contact:
    • Guangzhou
      • Guangdong, Guangzhou, China
        • The First Affiliated Hospital of Guangzhou Medical University
        • Contact:
      • Guangdong, Guangzhou, China
        • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome;
  • Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa;
  • Aged 18 to 85 years old;
  • Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy;
  • Patients or their family members have fully read, understood and signed the informed consent form.

Exclusion Criteria:

  • Women who are pregnant or lactating;
  • Patients with immunodeficiency;
  • Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases;
  • Patients who have received mechanical ventilation for more than 60 days prior to enrollment;
  • Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD);
  • Patients with incomplete sampling or clinical data;
  • Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula;
  • Patients judged by the researchers as unsuitable for participation in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: YHDF Placebo + Bacteriophage Placebo Group
7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo
Drug: YHDF placebo
7-14 days treatment with YHDF placebo
Drug: Bacteriophage Placebo
7-14 days treatment with bacteriophage placebo
Active Comparator: YHDF Placebo + Bacteriophage Group
7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo
Drug: YHDF placebo
7-14 days treatment with YHDF placebo
Drug: Bacteriophage
7-14 days treatment with bacteriophage
Active Comparator: YHDF Drug + Bacteriophage Placebo Group
7-14 days treatment with YHDF, 7-14 days treatment with phage placebo
Drug: Bacteriophage Placebo
7-14 days treatment with bacteriophage placebo
Drug: YHDF Drug
7-14 days treatment with YHDF
Active Comparator: YHDF Drug + Bacteriophage Group
7-14 days treatment with YHDF, 7-14 days treatment with phage
Drug: Bacteriophage
7-14 days treatment with bacteriophage
Drug: YHDF Drug
7-14 days treatment with YHDF

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Clearance rate of drug-resistant bacteria
Time Frame: 14 days
14 days

Secondary Outcome Measures

Outcome Measure
Time Frame
All-cause mortality
Time Frame: 28 days
28 days
Time to clinical improvement
Time Frame: 7 days
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese PLA General Hospital

Investigators

  • Study Director: Lixin Xie, College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

May 21, 2026

First Submitted That Met QC Criteria

May 21, 2026

First Posted (Actual)

May 29, 2026

Study Record Updates

Last Update Posted (Actual)

May 29, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025ZD05493-3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe